Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain
Portfolio Pulse from Vandana Singh
Labcorp and Roche are increasing their mpox testing capabilities in response to a new virus strain. Labcorp can scale up from 500 to 25,000 tests monthly, while Roche is leveraging its HIV testing infrastructure. Quest Diagnostics and Abbott Laboratories are also involved in mpox testing.
August 26, 2024 | 5:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abbott Laboratories has developed the Alinity m test kit for mpox, authorized for emergency use in the U.S.
Abbott's emergency use authorization for its mpox test kit could lead to increased sales and positively impact its stock.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 60
POSITIVE IMPACT
Quest Diagnostics offers mpox testing services as part of the response to the outbreak.
Quest Diagnostics' involvement in mpox testing could increase its service demand, potentially boosting its financial performance.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 60
POSITIVE IMPACT
Labcorp is collaborating with U.S. health regulators to potentially increase its mpox testing capacity from 500 to 25,000 tests monthly due to a new virus strain.
Labcorp's potential increase in testing capacity could lead to higher demand for its services, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Roche is monitoring global demand and exploring ways to use its HIV testing infrastructure for mpox testing.
Roche's adaptation of its existing infrastructure for mpox testing could enhance its market position and lead to increased revenue.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 70